Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Erin Larkins"'
Autor:
Harpreet Singh, Laleh Amiri-Kordestani, Amy Barone, Richard Pazdur, Mirat Shah, Janice Kim, Suparna Wedam, Diana Bradford, Gautam U Mehta, Erin Larkins, Adnan A. Jaigirdar, Marc R. Theoret, Lee Pai-Scherf, Julia A. Beaver
Publikováno v:
Journal of Neuro-Oncology
Objective Contemporary management of patients with neuro-oncologic disease requires an understanding of approvals by the US Food and Drug Administration (FDA) related to nervous system tumors. To summarize FDA updates applicable to neuro-oncology pra
Autor:
Julia A. Beaver, Whitney S. Helms, Harpreet Singh, Jiang Liu, Reena Philip, Diana Bradford, Dun Liang, Francisca Reyes Turcu, Amy M. Skinner, Rosane Charlab, Shenghui Tang, Soma Ghosh, Lauren S. L. Price, Marc R. Theoret, Richard Pazdur, Erin Larkins, Donna Roscoe, Yangbing Li, Jeanne Fourie Zirkelbach, Sirisha Mushti, Autumn Zack-Taylor, Lisa Rodriguez, Paul G. Kluetz
Publikováno v:
Clinical Cancer Research. 27:2130-2135
On May 8, 2020, the FDA granted accelerated approval to selpercatinib for (i) adult patients with metastatic RET fusion–positive non–small cell lung cancer (NSCLC), (ii) adult and pediatric patients ≥12 years of age with advanced or metastatic
Autor:
Xiaoxue Li, Pallavi S. Mishra-Kalyani, Sujay Shah, Erin Larkins, Jonathon Vallejo, Lisa Rodriguez, Luckson Mathieu, Lee Pai-Scherf, Kirsten B. Goldberg, Julia A. Beaver, Richard Pazdur, Paul G. Kluetz, Harpreet Singh, Marc R. Theoret
Publikováno v:
Oncologist
The U.S. Food and Drug Administration (FDA) granted approval to atezolizumab and durvalumab in March of 2019 and 2020, respectively, for use in combination with chemotherapy for first-line treatment of patients with extensive stage small cell lung ca
Autor:
Shanthi Marur, Rajeshwari Sridhara, Erin Larkins, Gideon M. Blumenthal, Richard Pazdur, Pallavi S. Mishra-Kalyani, Patricia Keegan, Harpreet Singh
Publikováno v:
Seminars in Oncology. 45:220-225
Among patients with newly diagnosed non-small cell lung cancer (NSCLC), approximately 70% occur in those above 65 years of age and more than half are metastatic or locally advanced NSCLC.Retrospective analyses pooling data across 4 randomized clinica
Autor:
Patricia Keegan, Amy E. McKee, Lauretta Odogwu, Xiaoping Jiang, Eunice Y. Lee, Richard Pazdur, Gideon M. Blumenthal, Luckson Mathieu, Reena Philip, Karen Bijwaard, Norma Griffin, Lisa Rodriguez, Kirsten B. Goldberg, Erin Larkins
Publikováno v:
The Oncologist
This article summarizes the FDA review of the efficacy supplement supporting approval of dabrafenib and trametinib administered concurrently for BRAF V600E‐mutant non‐small cell lung cancer.
On June 22, 2017, the Food and Drug Administration
On June 22, 2017, the Food and Drug Administration
Autor:
Sriram Subramaniam, Chao Liu, Kirsten B. Goldberg, Kun He, Weishi Yuan, Hong Zhao, Richard Pazdur, Patricia Keegan, Rajeshwari Sridhara, Gideon M. Blumenthal, Jingyu Yu, Amy E. McKee, Erin Larkins
Publikováno v:
The Oncologist
This article summarizes the evidence for the impact of BRAF mutations on treatment outcome of anti‐EGFR monoclonal antibodies. Based on a review of literature, eight meta‐analyses were included in this study, which consistently show that patients
Autor:
Patricia Keegan, Martha Donoghue, Eunice Y. Lee, Kirsten B. Goldberg, Erin Larkins, Karen Bijwaard, Ingrid Fan, Mallorie H. Fiero, Lauretta Odogwu, Luckson Mathieu, Reena Philip, Richard Pazdur, Gideon M. Blumenthal, Amy E. McKee, Lisa Rodriguez
Publikováno v:
The Oncologist
This article reviews the benefit‐risk assessment of osimertinib that led to approval of osimertinib for the treatment of patients with metastatic EGFR T790M mutation‐positive non‐small cell lung cancer whose disease had progressed after EGFR ty
Autor:
Amy E. McKee, Gina Davis, Kimberly Ringgold, Hong Zhao, Olen Stephens, Erin Larkins, Jingyu Yu, Whitney Helms, Huanyu Chen, Richard Pazdur, Kun He, Eias Zahalka, Gideon M. Blumenthal, Gerlie Gieser, Rajiv Agarwal, Patricia Keegan, Stacy Shifflett Shord
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(21)
On December 11, 2015, the FDA granted accelerated approval to alectinib (Alecensa; Genentech) for the treatment of patients with anaplastic lymphoma receptor tyrosine kinase (ALK)-positive, metastatic non–small cell lung cancer (NSCLC) who have pro
Autor:
Ramaswamy Govindan, Erin Larkins, Saiama N. Waqar, Fred R. Hirsch, Alice T. Shaw, Sean Khozin, Patricia Keegan, Leora Horn, Philip Bonomi, Tony Mok, Gregory J. Riely, Roy S. Herbst, Richard Pazdur, Pasi A. Jänne, Shakun Malik, Andrea Ferris, Dickran Kazandjian, Dane Dickson, Gideon M. Blumenthal, Vassiliki A. Papadimitrakopoulou
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 11(9)
Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment stra